Bruker BioSpin
1
22M
1
0.02
- Areas of investment
Summary
Bruker BioSpin appeared to be the Corporate Investor, which was created in 1975. The leading representative office of defined Corporate Investor is situated in the Billerica. The fund was located in North America if to be more exact in United States.
The typical case for the fund is to invest in rounds with 10 participants. The meaningful sponsors for the fund in investment in the same round are TaKaRa Shuzo, Perseus-Soros Biopharmaceutical Fund, OrbiMed.
The important activity for fund was in 2001. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there is Biotechnology. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight GeneFormatics.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.02
- Investments by industry
- Biotechnology (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2001
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 23
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.